Provectus Biopharmaceuticals, Inc.
PVCT · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $1 | $0 |
| % Growth | 10.7% | -43.6% | – | – |
| Cost of Goods Sold | $0 | $2 | $0 | $0 |
| Gross Profit | $1 | -$1 | $1 | -$0 |
| % Margin | 98.8% | -204.8% | 93.6% | – |
| R&D Expenses | $2 | $2 | $2 | $3 |
| G&A Expenses | $3 | $1 | $2 | $2 |
| SG&A Expenses | $3 | $1 | $2 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$1 | -$1 | -$1 | -$0 |
| Operating Expenses | $5 | $3 | $3 | $5 |
| Operating Income | -$4 | -$3 | -$3 | -$5 |
| % Margin | -640.8% | -520.2% | -346.6% | – |
| Other Income/Exp. Net | -$1 | -$0 | -$0 | -$1 |
| Pre-Tax Income | -$5 | -$3 | -$4 | -$6 |
| Tax Expense | -$0 | -$0 | $0 | $0 |
| Net Income | -$5 | -$3 | -$4 | -$6 |
| % Margin | -766.9% | -556.2% | -359.3% | – |
| EPS | -0.011 | -0.007 | -0.009 | -0.016 |
| % Growth | -52.7% | 12.9% | 46.5% | – |
| EPS Diluted | -0.011 | -0.007 | -0.009 | -0.016 |
| Weighted Avg Shares Out | 420 | 420 | 419 | 408 |
| Weighted Avg Shares Out Dil | 420 | 420 | 419 | 408 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$5 | -$3 | -$3 | -$5 |
| % Margin | -733.2% | -518.5% | -340.1% | – |